Bucillamine: A Unique Antirheumatic Drug with Different Properties and Possible Mode of Actions

Abstract

Bucillamine the drug instigated in the 1990s for the treatment of Rhematoidal Arthritis. This antirheumatic agent evaluated from troponin. A life sciences company Revive Therapeutics is exploring various uses and different properties of the drug Bucillamine as a unique remedy for the treatment of disease like infectious diseases involving influenza and the coronavirus disease (COVID-19). Oral administration of this novel drug is used broadly in Asia for rheumatoid arthritis. Revive has also suggested Bucillamine use for the prevention of acute gout flares with proven data of Phase 2 study conducted in U.S. Bucillamine is now being investigated for COVID-19. Bucillamine with multiple properties to prevent damage associated with myocardial infarction, cardiac surgery and organ transplantation. A strong data suggest that bucillamine in acute inflammation and oxidative stress and materialize to have anti-inflammatory effects and antioxidant effect. Bucillamine is a potent thiol donor cysteine derivative with effective therapeutic activities like Photo protective effect, reperfusion injury, Immunomodulatory, Diabetic nephropathy, Ulcerative colitis. Moreover, Bucillamine treatment significantly increased levels of oxidized glutathione’s, it prevents accumulation of toxic oxygen species, interruption of redox signaling, inhibition of macrophage activation. Revive is exploring a product and clinical development plan deliberated to unseal the full prospective of Bucillamine.